Tirzepatide 15mg
$199.00
Tirzepatide was originally developed for the treatment of type 2 diabetes and has also demonstrated cardioprotective effects. It is a synthetic analog of gastric inhibitory polypeptide (GIP) that also exhibits glucagon-like peptide-1 (GLP-1) receptor agonist activity. This dual mechanism of action enables Tirzepatide to effectively lower blood glucose levels, enhance insulin sensitivity, and promote satiety.
TIRZEPITIDE
Tirzepatide is a once-weekly injectable medication designed to treat type 2 diabetes and support weight management. It is a synthetic peptide that acts as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By mimicking the activity of these two incretin hormones, Tirzepatide enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes a sense of satiety.
Clinical trials have demonstrated Tirzepatide’s effectiveness in improving glycemic control, reducing body weight, and providing potential cardiovascular benefits. Its dual-action mechanism sets it apart from traditional GLP-1 receptor agonists, offering a more comprehensive approach to metabolic regulation. Due to these properties, Tirzepatide has gained significant attention in both endocrinology and obesity research.
